Literature DB >> 29913273

Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis.

Neeraj Narula1, Abdul-Aziz Alshahrani2, Yuhong Yuan2, Walter Reinisch3, Jean-Frederic Colombel4.   

Abstract

BACKGROUND & AIMS: We aimed to evaluate the association of the patient-reported outcomes for rectal bleeding and stool frequency among patients with ulcerative colitis (UC) in endoscopic remission.
METHODS: We performed a systematic review of studies reporting the association of patient-reported outcomes (the patient-reported components of the Mayo score: rectal bleeding and stool frequency) and endoscopic remission (Mayo endoscopic subscore of 0 or 1). We performed a meta-analysis of diagnostic accuracy using the hierarchical bivariate method.
RESULTS: Our meta-analysis consisted of 5 studies comprising 2132 participants. A rectal bleeding subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 81% (95% CI, 73%-86%), a specificity value of 68% (95% CI, 61%-75%), a positive likelihood ratio (LR) of 2.5 (95% CI, 2.2-3.0), and a negative LR of 0.28 (95% CI, 0.22-0.37). A stool frequency subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 40% (95% CI, 25%-58%), a specificity value of 93% (95% CI, 86%-97%), a positive LR of 6.0 (95% CI, 3.7-9.7), and negative LR of 0.64 (95% CI, 0.50-0.82). A combined rectal bleeding and stool frequency subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 36% (95% CI, 22%-54%), a specificity value of 96% (95% CI, 91%-98%), a positive LR or 8.4 (95% CI, 5.5-12.8), and a negative LR or 0.66 (95% CI, 0.53-0.84).
CONCLUSIONS: In a meta-analysis of 5 studies, we found that most patients with UC and normal rectal bleeding and stool frequency subscores have attained endoscopic remission. Many patients in endoscopic remission from UC have no rectal bleeding. Normal stool frequency associates with endoscopic remission, but many patients have abnormal stool frequencies despite endoscopic remission. These results should be carefully considered given the high heterogeneity and wide confidence intervals for some outcomes.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IBD; Inflammatory Bowel Diseases; Response to Therapy; Treatment Outcome

Mesh:

Year:  2018        PMID: 29913273     DOI: 10.1016/j.cgh.2018.06.015

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  Tofacitinib: A Jak of All Trades.

Authors:  Kristin E Burke; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

2.  Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.

Authors:  Siddharth Singh; James A Proudfoot; Parambir S Dulai; Ronghui Xu; Brian G Feagan; William J Sandborn; Vipul Jairath
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-18       Impact factor: 11.382

3.  Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.

Authors:  Christopher Ma; William J Sandborn; Geert R D'Haens; Guangyong Zou; Larry W Stitt; Siddharth Singh; Ashwin N Ananthakrishnan; Parambir S Dulai; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-09-20       Impact factor: 11.382

4.  Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.

Authors:  Parambir S Dulai; Siddharth Singh; Vipul Jairath; Christopher Ma; Neeraj Narula; Niels Vande Casteele; Laurent Peyrin-Biroulet; Severine Vermeire; Geert D'Haens; Brian G Feagan; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2019-11-22       Impact factor: 8.171

5.  US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.

Authors:  Berkeley N Limketkai; Siddharth Singh; Vipul Jairath; William J Sandborn; Parambir S Dulai
Journal:  Inflamm Bowel Dis       Date:  2019-10-18       Impact factor: 5.325

6.  Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis.

Authors:  Yan Li; Michael Khamou; Benedikt Michael Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Johannes Haubold; Anna Katharina Koch; Nils-Martin Bruckmann; Lino Morris Sawicki; Ken Herrmann; James Hunter Boone; Jost Langhorst
Journal:  Br J Radiol       Date:  2020-06-24       Impact factor: 3.039

7.  Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.

Authors:  Stephen Hanauer; William J Sandborn; Jean-Frederic Colombel; Severine Vermeire; Joel Petersson; Kristina Kligys; Qian Zhou; Andreas Lazar; Walter Reinisch
Journal:  J Crohns Colitis       Date:  2019-09-19       Impact factor: 9.071

8.  Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients.

Authors:  Sanja Dragasevic; Aleksandra Sokic-Milutinovic; Milica Stojkovic Lalosevic; Tamara Milovanovic; Srdjan Djuranovic; Ivan Jovanovic; Sanja Rajic; Mirjana Stojkovic; Biljana Milicic; Stefan Kmezic; Branislav Oluic; Marko Aleksic; Aleksandra Pavlovic Markovic; Dragan Popovic
Journal:  Gastroenterol Res Pract       Date:  2020-04-02       Impact factor: 2.260

9.  Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.

Authors:  Charlie W Lees; J Jasper Deuring; Michael Chiorean; Marco Daperno; Gianluca Bonfanti; Rebecca Germino; Pritha Bhadra Brown; Irene Modesto; Roger A Edwards
Journal:  Therap Adv Gastroenterol       Date:  2021-11-29       Impact factor: 4.409

10.  Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study.

Authors:  Christian Maaser; Frauke Petersen; Ulf Helwig; Imma Fischer; Alexander Roessler; Stefan Rath; Dorothee Lang; Torsten Kucharzik
Journal:  Gut       Date:  2019-12-20       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.